Skip to main content
. Author manuscript; available in PMC: 2023 Aug 9.
Published in final edited form as: Hepatology. 2023 Feb 20;78(1):243–257. doi: 10.1097/HEP.0000000000000307

Figure 1: p16 expression is reduced in HFD fed mice after treatment with p16 VM.

Figure 1:

WT HFD fed mice injected with control VM showed a robust increase in p16 immunoreactivity (green) in cholangiocytes (red, A) and in hepatocytes (magenta, B). p16 VM injection in HFD mice reduced p16 immunostaining in both cholangiocytes (A) and hepatocytes (B). There were visible differences between the CD control VM and p16 VM injected groups. In human NAFLD and NASH, p16 immunoreactivity (p16, green) increased in both cholangiocytes (red) and hepatocytes (magenta) compared to normal control (C). Representative images from n = 4 are shown at 40x and 20x, respectively for the mouse and 100x for human staining (n = 4).